Key statistics
As of last trade Ligand Pharmaceuticals Inc (LGDN:FRA) traded at 94.00, -8.74% below its 52-week high of 103.00, set on Jul 31, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 93.00 |
---|---|
High | 94.00 |
Low | 93.00 |
Bid | 93.50 |
Offer | 95.00 |
Previous close | 92.50 |
Average volume | 4.00 |
---|---|
Shares outstanding | 18.27m |
Free float | 17.88m |
P/E (TTM) | 46.60 |
Market cap | 1.89bn USD |
EPS (TTM) | 2.22 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 15:07 BST.
More ▼
Press releases
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
- Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Ligand Reports Second Quarter 2024 Financial Results
- Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
- Ligand to Acquire APEIRON Biologics AG for $100 Million
- Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
More ▼